Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2013, Pages 71-74

  Tomaru, Atsuko ^a   Morimoto, Nozomi ^a   Morishita, Mariko ^a   Takayama, Kozo ^a   Fujita, Takuya ^b   Maeda, Kazuya ^c   Kusuhara, Hiroyuki ^c   Sugiyama, Yuichi ^c  

^a HOSHI UNIVERSITY   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

BCRP; Everted sac; Intestinal absorption; Sulfasalazine; Transporter

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DIMETHYL SULFOXIDE; KO 134; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN INHIBITOR; PROTEIN OATP1A2; PROTEIN OATP2B1; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ACCLIMATIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; BINDING AFFINITY; DRUG ABSORPTION; DRUG CLEARANCE; FEMALE; HUMIDITY; IC 50; IN VITRO STUDY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; NOTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TANDEM MASS SPECTROMETRY;

EID: 84874600093     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-NT-024     Document Type: Article

References (25)

1. Peppercorn, M. A.: Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann. Intern. Med., 101: 377-386 (1984).
2. Rains, C. P., Noble, S. and Faulds, D.: Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs, 50: 137-156 (1995).
3. Houston, J. B., Day, J. and Walker, J.: Azo reduction of sulphasalazine in healthy volunteers. Br J. Clin. Pharmacol, 14: 395-398 (1982).
4. Peppercorn, M. A. and Goldman, P.: The role of intestinal bacteria in tire metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Then, 181: 555-562 (1972).
5. Bird, H. A.: Sulphasalazine, sulphapyridine or 5-aminosalicylic acid-which is die active moiety in rheumatoid arthritis? Br. J. Rheumatol, 34 (Suppl. 2): 16-19 (1995).
6. Pullar, T., Hunter, J. A. and Capell, H. A.: Which component of sulphasalazine is active in rheumatoid arthritis? Br. Med. J. (Clin. Res. Ed.), 290: 1535-1538 (1985).
7. Das, K. M. and Dubin, R.: Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet, 1: 406-425 (1976).
8. Klotz, U.: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet., 10: 285-302 (1985).
9. Yazdanian, M., Glynn, S. L., Wright, J. L. and Hawi, A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res., 15: 1490-1494 (1998).
10. van der Heijden, J., de Jong, M. C, Dijkmans, B. A. C, Lems, W. E, Oerlemans, R., Kathmann, I., Schalkwijk, C. G., Scheffer, G. L., Scheper, R. J. and Jansen, G.: Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2(BCRP) and augmented production of TNFa. Ann. Rheum. Dis., 63: 138-143 (2004).
11. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J. and Schellens, J. H. M.: Subcellular localization and distribution of die breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464 (2001).
12. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L. and Ware, J. A.: Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in die mouse. Mol. Pharm., 3: 55-61 (2006).
13. Dahan, A. and Amidon, G. L.: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol, 297: G371-G377 (2009).
14. Dahan, A. and Amidon, G. L.: MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in die small intestine, potentially decreasing its colonic targeting. Int. J. Pharm., 386: 216-220 (2010).
15. Yamasaki, Y, Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y, Irie, S., Ware, J. A., Nakai, Y, Higuchi, S. and Sugiyama, Y: Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2(BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther, 84: 95-103 (2008).
16. Urquhart, B. L., Ware, J. A., Tirana, R. G., Ho, R. H., Leake, B. F., Schwarz, U. I., Zaher, H., Palandra, J., Gregor, J. C, Dresser, G. K. and Kim, R. B.: Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics, 18: 439-448 (2008).
17. Kusuhara, H., Furuie, H., Inano, A., Sunagawa, A., Yamada, S., Wu, C, Fukizawa, S., Morimoto, N., Ieiri, I., Morishita, M., Sumita, K., Mayahara, H., Fujita, T., Maeda, K. and Sugiyama, Y: Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br. J. Pharmacol, 166: 1793-1803 (2012).
18. Enokizono, J., Kusuhara, H. and Sugiyama, Y: Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab. Dispos., 35: 922-928 (2007).
19. Solvo Biotechnology: http://www.solvobiotech.com/products/categories/ko134-bcrp-specific-inhibitor.
20. MacLean, C, Moenning, U., Reichel, A. and Flicker, G.: Closing the gaps: a full scan of die intestinal expression of P-glycopratein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Discos., 36: 1249-1254 (2008).
21. Jani, M., Szabo, P., Kis, E., Molriar, E., Glavinas, H. and Krajcsi, P.: Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol. Pharm. Bull, 32: 497-499 (2009).
22. Tachibana, T., Kato, M., Watanabe, T., Mitsui, T. and Sugiyama, Y: Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica, 39: 430-443 (2009).
23. Shirasaka, Y, Li, Y, Shibue, Y, Kuraoka, E., Spahn-Langguth, H., Kato, Y, Langguth, P. and Tamai, I.: Concentration-dependent effect of naringin on intestinal absorption of /Ji-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res., 26: 560-567 (2009).
24. Shirasaka, Y, Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P. and Tamai, I.: Species difference in die effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther, 332: 181-189 (2010).
25. Terhaag, B., Palm, U., Sahre, H., Richter, K. and Oertel, R.: Interaction of talinolol and sulfasalazine in die human gastrointestinal tract. Eur J. Clin. Pharmacol, 42: 461-462 (1992).